Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.23 USD
Change Today +0.01 / 0.82%
Volume 93.2K
TBIO On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 8:10 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

transgenomic inc (TBIO) Snapshot

Open
$1.22
Previous Close
$1.22
Day High
$1.25
Day Low
$1.18
52 Week High
10/6/14 - $4.39
52 Week Low
08/24/15 - $1.04
Market Cap
17.1M
Average Volume 10 Days
198.2K
EPS TTM
$-1.84
Shares Outstanding
13.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TRANSGENOMIC INC (TBIO)

Related News

No related news articles were found.

transgenomic inc (TBIO) Related Businessweek News

No Related Businessweek News Found

transgenomic inc (TBIO) Details

Transgenomic, Inc., a biotechnology company, engages in advancing personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and clinical and research services in the United States and internationally. It operates in two segments, Laboratory Services, and Genetic Assays and Platforms. The Laboratory Services segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders, and oncology. This segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies. In addition, it employs various genomic testing service technologies, including ICE COLD-PCR technology, a proprietary platform technology that enables detection of multiple known and unknown mutations from virtually any sample type, including tissue biopsies, blood, urine, saliva, cell-free DNA, and circulating tumor cells. The Genetic Assays and Platforms segment offers the WAVE System, which has applicability to genetic variation detection in molecular genetic research and molecular diagnostics. It also manufactures and sells consumable products, including a range of chromatography columns, which can be used on multiple and independent platforms. The company sells its products through direct sales, support staff, dealers, and distributors to pharmaceutical, biotech, and commercial companies, as well as academic and medical institutions. Transgenomic, Inc. has a collaboration agreement with PDI, Inc. The company was founded in 1997 and is headquartered in Omaha, Nebraska.

150 Employees
Last Reported Date: 04/15/15
Founded in 1997

transgenomic inc (TBIO) Top Compensated Officers

Chief Executive Officer, President, Interim C...
Total Annual Compensation: $350.0K
Chief Accounting Officer and Controller
Total Annual Compensation: $182.5K
Compensation as of Fiscal Year 2014.

transgenomic inc (TBIO) Key Developments

Transgenomic Inc. Launches New MX-ICP EGFR Analysis Lung Cancer Panel

Transgenomic Inc. has launched new MX-ICP EGFR Analysis lung cancer panel. The new EGFR panel covers key actionable mutations while providing precision detection levels down to as low as 0.01%. The panel uses Transgenomic's Multiplexed ICE COLD-PCR (MX-ICP) technology, which generates highly accurate results from small amounts of blood or tissue samples and is available for diagnostic use through the company's CLIA laboratory. The panel adds to the mutations included in the company's first EGFR tests launched in May, adding mutations in EGFR exons 18-21 that are associated with resistance to tyrosine kinase inhibitor (TKI) cancer drugs and broadening the testing options available to the oncologist. Transgenomic's EGFR panels address all of the known mutations that affect EGFR status and the likely efficacy of TKI drugs for the patient's cancer. Characteristic mutations in the epidermal growth factor receptor (EGFR) are found in many patients with lung tumors, and these mutations may be associated with susceptibility or resistance to certain targeted cancer drugs. The launch of this new EGFR panel soon after the debut of first CLIA cancer tests reflects commitment to making Multiplexed ICE COLD-PCR-based tests widely available to patients Transgenomic's first EGFR tests were for the detection of EGFR exon 20 T790M mutations that indicate if the NSCLC tumor has developed resistance to TKI drugs and EGFR exon 12 S492R mutations that render colorectal tumors resistant to cetuximab. The new MX-ICP EGFR Analysis panel includes EGFR exons 18-21 to determine NSCLC tumor sensitivity or resistance to tyrosine kinase inhibitors. Multiplexed ICE COLD-PCR achieves its ultra-high sensitivity through selective amplification of mutant DNA. The result is up to a 500-fold increase in sensitivity in identifying mutations with the most precise sequence alteration detection rates available-down to 0.01% from as little as a 4 ml of plasma sample, making it possible to obtain accurate and sensitive biopsies using either liquid or solid tissue specimens. ICE COLD-PCR was originally developed by the laboratory of Dr. Mike Makrigiorgos at the Dana-Farber Cancer Institute, which has exclusively licensed rights to the technology to Transgenomic.

Transgenomic, Inc. Adds Spectron Scientific Co., Ltd. and Sowa Trading Co., Inc. as Asia Distributors for its ICEme Kits That Enable Liquid Biopsy-Based Genomics Cancer Research on Existing Platforms

Transgenomic, Inc. announced the addition of distributors in China and Japan for its ICEme Mutation Enrichment Kits for genomics research. The recently-launched kits use Transgenomic’s Multiplexed ICE COLD-PCR (MX-ICP) technology and are designed to facilitate genomics-based cancer research. The new distributors include Spectron Scientific Co. Ltd. in China and Sowa Trading Co., Inc., in Japan, who are established suppliers of advanced life science products to researchers at universities, pharmaceutical and biotech companies, and research institutes in their respective markets.

Transgenomic, Inc. Launches New MX-ICP Panel for Lung Cancer That Accurately Detects Key EGRF Mutations in Blood

Transgenomic Inc. announced the launch of its MX-ICP EGFR Analysis lung cancer panel that covers key actionable mutations while providing precision detection levels down to as low as 0.01%. The panel uses Transgenomic’s Multiplexed ICE COLD-PCR™ (MX-ICP) technology, which generates highly accurate results from small amounts of blood or tissue samples and is available for diagnostic use through the company’s CLIA laboratory. The panel adds to the mutations included in the company’s first EGRF tests launched in May, adding mutations in EGRF exons 18-21 that are associated with resistance to tyrosine kinase inhibitor (TKI) cancer drugs and broadening the testing options available to the oncologist. Transgenomic’s EGRF panels address all of the known mutations that affect EGFR status and the likely efficacy of TKI drugs for the patient’s cancer. Characteristic mutations in the epidermal growth factor receptor (EGFR) are found in many patients with lung tumors, and these mutations may be associated with susceptibility or resistance to certain targeted cancer drugs. For example, 85% of EGFR mutations in patients with non-small cell lung cancer (NSCLC) indicate that the tumor is sensitive to TKI’s1, while a different EGFR mutation is associated with resistance to TKIs2. Transgenomic’s EGFR panels include all the mutations listed in the guidelines for EGFR mutation testing issued by the American Society of Clinical Oncology [1] (ASCO) and the National Comprehensive Cancer Network. Transgenomic’s first EGFR tests were for the detection of EGFR exon 20 T790M mutations that indicate if the NSCLC tumor has developed resistance to TKI drugs and EGFR exon 12 S492R mutations that render colorectal tumors resistant to cetuximab. The new MX-ICP EGFR Analysis panel includes EGFR exons 18-21 to determine NSCLC tumor sensitivity or resistance to tyrosine kinase inhibitors. Multiplexed ICE COLD-PCR achieves its ultra-high sensitivity through selective amplification of mutant DNA. The result is up to a 500-fold increase in sensitivity in identifying mutations with the most precise sequence alteration detection rates available--down to 0.01% from as little as a 4 ml of plasma sample, making it possible to obtain accurate and sensitive biopsies using either liquid or solid tissue specimens. ICE COLD-PCR was originally developed by the laboratory of Dr. Mike Makrigiorgos at the Dana-Farber Cancer Institute, which has exclusively licensed rights to the technology to Transgenomic. Additional tests and panels for mutations in KRAS, NRAS, PIK3CA, BRAF and other genes are in development.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TBIO:US $1.23 USD +0.01

TBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Foundation Medicine Inc $23.32 USD -0.38
Illumina Inc $193.16 USD -2.29
QIAGEN NV €23.17 EUR -0.67
Quest Diagnostics Inc $65.17 USD -1.76
Sequenom Inc $1.97 USD -0.03
View Industry Companies
 

Industry Analysis

TBIO

Industry Average

Valuation TBIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.5x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TRANSGENOMIC INC, please visit www.transgenomic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.